Food-effect Study of Ecopipam Pharmacokinetics

Completed · Phase 1

Conditions studied: Food-effect

In brief

Standard food-effect study to identify the effect of food on ecopipam pharmacokinetics after administration of a to-be-marketed ecopipam tablet in healthy volunteers.

Key facts

Study ID

NCT06669091

Run by

Emalex Biosciences Inc.

People needed

25

Starts

2024-11-05

Expected to finish

2024-12-27

Last updated by the study team

2025-01-27

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male subjects or female subjects of non-childbearing potential
• ≥18 and ≤55 years of age
• BMI >18.5 and <30.0 kg/m2 and body weight ≥50.0 kg for males and ≥45.0 kg for females.
• Subjects must be healthy, as determined by the Investigator, based on medical history, physical examination, ECG, vital signs, and standard panel of blood and laboratory tests at Screening.
• Sexually active males must use a double barrier method of contraception during the study and for at least 90 days after the last dose of study drug.
• Male subjects must be willing not to donate sperm until 90 days following the last study drug administration.

You may not qualify if…

• History of significant medical illness
• Clinically significant abnormalities on screening tests/exams
• History of or significant risk of committing suicide
• Donation of plasma within 1 month prior to dosing
• Donation or significant loss of blood within 8 weeks prior to the first dosing
• Major surgery within 3 months or minor surgery within 1 month prior to admission
• Use of prohibited prescription, over-the-counter medications or natural health products
• Use of tobacco or nicotine products within 1 month prior to Screening
• Significant alcohol consumption or history of abuse
• History of drug abuse within the previous 2 years, or a positive drug screen
• History of cannabinoid use within the previous 3 months
• Positive urine drug screen, urine cotinine test, or alcohol breath test
• History of allergy to study medications
• Recent participation in a clinical research study
• Prior exposure to ecopipam
• Not suitable for study in the opinion of the Principal Investigator

Where it is running

• ICON Early Phase Services — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.